间歇性跛行与慢性肢体威胁性缺血患者再干预比较
单中心回顾性研究纳入2013-2015年因PAD行下肢血运重建的826例患者,44%为CLTI。CLTI患者30天及长期截肢和死亡率更高,同侧再干预率无差异,但调整随访时间后CLTI患者每年再干预次数显著更高。
要点
- CLTI患者长期大截肢率15.5% vs 跛行1.3%,死亡率37.1% vs 18.1%。
- 两组同侧再干预率无显著差异(39.6% vs 42.7%,P=0.37)。
核心结论
- 因CLTI行下肢血运重建的患者随时间推移比跛行患者接受更频繁的再干预。
研究设计与样本
- 单中心回顾性病历审查,纳入2013-2015年连续因PAD行下肢血运重建的826例患者,按适应证分为跛行组和CLTI组。
主要发现
- CLTI患者吸烟、糖尿病、慢性肾功能不全、终末期肾病和心脏病比例均更高(P<0.001)。
- CLTI患者阿司匹林、ADP受体/P2Y12抑制剂和他汀使用率均更低(P<0.001)。
- 30天大截肢率CLTI 3.7% vs 跛行0.2%(P<0.001),死亡率1.4% vs 0.2%(P=0.092)。
- 长期大截肢率CLTI 15.5% vs 跛行1.3%(P<0.001),死亡率37.1% vs 18.1%(P<0.001)。
- 同侧再干预率无显著差异(39.6% vs 42.7%,P=0.37),平均同侧再干预次数均为2.0±1.6 vs 2.0±1.7。
关键数值与推荐
- 平均随访时间跛行组3.7±1.5年,CLTI组2.6±1.8年(P<0.001)。
临床怎么用
- CLTI患者下肢血运重建后需更密集的再干预计划,并应加强优化药物治疗。
- 研究报告中除再干预率外,应报告经随访时间调整的再干预频率。
局限性
- 单中心回顾性设计可能限制结果外推。
- 两组随访时间存在显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with peripheral artery disease (PAD) present with claudication or chronic limb threatening ischemia (CLTI). CLTI patients have a more advanced stage of atherosclerosis and increased comorbidities compared to claudicants, and are at an elevated risk of major amputation and mortality after lower extremity revascularization (LER). However, the frequency of reinterventions for claudication and CLTI have not been compared. Our hypothesis is that patients with CLTI undergo more frequent reinterventions to prevent major amputation. METHODS: A single-center retrospective chart review of consecutive patients undergoing lower extremity revascularization (LER) for PAD in 2013-2015 was performed. Patients were stratified based on indication for revascularization into claudication or CLTI. Patient characteristics, outcomes, and reinterventions were compared between the 2 groups. RESULTS: There were 826 patients undergoing LER and 44% (N = 361) had CLTI. Patients treated for CLTI were more likely to be smokers (P < 0.001), to have diabetes (P< 0.001), chronic renal insufficiency (P< 0.001), end stage renal disease (P< 0.001), and cardiac disease (P< 0.001). CLTI patients were less likely to be on optimal medical management as reflected by decreased rate of aspirin (P< 0.001), ADP receptor/P2Y12 inhibitors (P< 0.001), and statins (P< 0.001) compared to patients with claudication. Patients with CLTI had significantly higher major amputation (3.7% vs. 0.2%, P< 0.001) and mortality (1.4% vs. 0.2%, P = 0.092) at 30 days. At long-term follow up, patients with CLTI had higher rates of major amputation (15.5% vs. 1.3%, P < 0.001) and mortality (37.1% vs. 18.1%, P < 0.001) compared to patients with claudication. There was a significant difference in mean follow-up time between the 2 cohorts (claudication: 3.7 ± 1.5 years versus CLTI: 2.6 ± 1.8 years, P < 0.001). There was no significant difference in the ipsilateral reintervention rate between the 2 groups (claudication: 39.6% vs. CLTI: 42.7%, P = 0.37) or the mean number of ipsilateral reinterventions (claudication: 2.0 ± 1.6 vs. CLTI: 2.0 ± 1.7). However, after adjusting for follow-up time, the mean number of reinterventions per year was significantly higher for CLTI patients compared to patients with claudication (1.4 ± 2.2 vs. .6 ± 0.7 intervention per year, P < 0.001). CONCLUSIONS: Patients undergoing LER for CLTI undergo more frequent reinterventions over time compared to patients treated for claudication. Research on reinterventions after LER should include reporting of the frequency of reintervention adjusted for the follow up period in addition to the reintervention rate defined as the percentage of patients undergoing reintervention.
引用
- Mohamedali A, Kiwan G, Kim T, et al. Reinterventions in Patients with Claudication and Chronic Limb Threatening Ischemia. Ann Vasc Surg. 2021. PMID: 34656724. doi:10.1016/j.avsg.2021.07.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。